CFO equity grants at BridgeBio Oncology Therapeutics (BBOT)

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported that Chief Financial Officer Uneek Mehra received new equity awards. On March 10, 2026, he was granted stock options covering 105,000 shares of common stock at an exercise price of $10.19 per share, expiring on March 9, 2036.

The option vests in substantially equal monthly installments, with 1/48 of the shares vesting each month from January 1, 2026, contingent on continued service. He also received 23,330 restricted stock units, each representing one share of common stock, vesting in 16 equal quarterly installments over four years from January 1, 2026, and settling in shares upon vesting.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Mehra Uneek

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	105,000	$0.00	--
Grant/Award	Common Stock	23,330	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 105,000 shares (Direct); Common Stock — 23,330 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehra Uneek

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		23,330(1)	A	$0	23,330	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.19	03/10/2026		A		105,000		(2)	03/09/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Uneek Mehra	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did BBOT’s CFO receive in this Form 4 filing?

The CFO received stock options for 105,000 shares at an exercise price of $10.19 and 23,330 restricted stock units. Both awards are service-based and vest over multi-year schedules starting from January 1, 2026, aligning compensation with long-term company performance.

How do the new stock options for BBOT’s CFO vest over time?

The stock options covering 105,000 shares vest in 48 substantially equal monthly installments. Each month, 1/48 of the grant becomes exercisable starting from January 1, 2026, provided the CFO remains in continuous service with BridgeBio Oncology Therapeutics on each vesting date.

What are the vesting terms of the RSUs granted to BBOT’s CFO?

The 23,330 RSUs vest in 16 equal quarterly installments over four years from January 1, 2026. Each vested RSU will be settled in one share of common stock, assuming the CFO maintains continuous service with the company through each quarterly vesting date.

Does the BBOT Form 4 indicate any stock sales by the CFO?

The Form 4 only shows acquisitions through equity grants, not any stock sales. It reports a stock option grant and an RSU grant, both with multi-year vesting schedules tied to continued service, and no open-market purchases or dispositions are included in this filing.

What is the exercise price and expiration for BBOT CFO’s new options?

The CFO’s newly granted stock options have an exercise price of $10.19 per share and an expiration date of March 9, 2036. These options gradually become exercisable over 48 months beginning on January 1, 2026, subject to his continued service.

How many BBOT shares does the CFO hold after these equity grants?

Following these grants, the CFO directly holds 23,330 shares of common stock from the RSU award and stock options for 105,000 underlying shares. These positions reflect newly awarded equity subject to the specified vesting schedules and service conditions in the disclosure.